|Product Specs||HyperRho® S/D|
For prevention of isoimmunization in Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks’ gestation.
|Contraindications||None known. Rho(D) Immune Globin (Human) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immune globulin preparations|
|Viral Safety Process||Precipitation, depth filtration, solvent/detergent treatment. The final container incubation step used during the manufacture of HyperRho S/D contributes to virus inactivation.|
|Route of Administration||Intramuscular|
|Clearance of Rh-positive Red Blood Cells||Mini-Dose
Each single dose syringe contains sufficient anti-Rho(D) to effectively suppress the immunizing potential of 2.5 mL of Rho(D) positive packed red blood cells or the equivalent of whole blood (5 mL).
|Product Half-Life||Approx. 23-26 days|
|Latex Content||HyperRhO S/D mini-dose and HyperRho S/D full dose prefilled disposable syringes in a latex-free delivery system.|
|Shelf Life||36 months from manufactured date|
|Supply Method||Preservative (thimerosol)-free, prefilled disposable syringes with attached UltraSafe Needle Guard in a latex-free delivery system|
|Available Sizes||Mini-Dose: 250 IU prefilled disposable syringe in 10pk
Full Dose: 1500 IU prefilled disposable syringe in 10pk and single syringe
Return to Manufacturer Name listing Return to Factor Type listing